Mirtazapine in social anxiety disorder: a pilot study.
Fourteen patients with social anxiety disorder (generalized type), according to DSM-IV criteria, were treated with mirtazapine 30 mg for 12 weeks. Twelve patients completed the study. Two patients (14.3%) dropped out due to side-effects. Generally, mirtazapine was well tolerated. Five out of 12 patients (41.7%) were classified as responders, based on a Clinical Global Improvement score of 1 or 2 and a reduction of the Liebowitz Social Anxiety Scale (LSAS) of 40%. The mean total score on the LSAS, as well as the anxiety and avoidance subscores, decreased significantly. This open pilot study suggests that further investigations are warranted to prove the efficacy of mirtazapine in generalized social anxiety disorder.
Van Veen
J F
JF
Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands. j.f.van.veen@lumc.nl
Van Vliet
I M
IM
Westenberg
H G M
HG
D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology*; D000078785:Mirtazapine; D010352:Patient Dropouts; D010698:Phobic Disorders / Q000188:drug therapy* / Q000523:psychology; D010865:Pilot Projects; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000929:Antidepressive Agents, Tricyclic; D008803:Mianserin; D000078785:Mirtazapine